Perspectives on PARP Inhibitors in Ovarian Cancer

Has the Time Come for Individualized Care?

Activity Goals

Epidemiology: Ovarian Cancer

PARP and DNA Repair

BRCA and DNA Repair

Synthetic Lethality Is Associated With Inhibition of PARP in the Presence of BRCA Deficiency

PARP Inhibition in BRCA-like Solid Tumors

Repair Mechanisms and BRCAness

BRCA Testing: When Should it Be Done?

PARP Inhibition: Mechanism of Action

Clinical Outcomes in Patients With BRCA Mutations

PARP Inhibitors in Clinical Trials

Case Study 1

Treatment Options

Anticipated PFS With Standard Treatment

Olaparib as Maintenance Therapy: Study Design

Results of BRCA Testing

Results

ASCO 2014: Cediranib/Olaparib

PFS With Cediranib/Olaparib Superior to Olaparib Alone

PFS Increased With Cediranib/Olaparib Combination

Phase 2: PLD vs Olaparib

Case Study 2

Treatment Approach

Neoadjuvant Chemotherapy (NACT) vs Primary Debulking

Surgery (PDS)

Dose-Dense Paclitaxel + Carboplatin vs Conventional

Regimen

BRCAness and Response to Chemotherapy

GOG9923

Key Issues for Future Developments

of PARP Inhibitors

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)